Galectin-3 and CD44v6 as markers for preoperative diagnosis of thyroid cancer by RT-PCR

Diagnostic Molecular Pathology

Volumn 20, Issue 4, 2011, Pages 233-241

  Šamija, Ivan ^a   Mateša, Neven ^a   Lukač, Josip ^a   Kusić, Zvonko ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

biological tumor markers; CD44v6 antigen; fine needle biopsy; galectin 3; reverse transcriptase polymerase chain reaction; thyroid neoplasms; thyroid nodule

Indexed keywords

CD44V6 ANTIGEN; GALECTIN 3; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER DIAGNOSIS; CYTODIAGNOSIS; DIAGNOSTIC VALUE; FEMALE; HASHIMOTO DISEASE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NODULAR GOITER; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SENSITIVITY AND SPECIFICITY; THYROID ADENOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID PARAFOLLICULAR CELL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; DIAGNOSIS, DIFFERENTIAL; FEMALE; GALECTIN 3; GOITER, NODULAR; HASHIMOTO DISEASE; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID NEOPLASMS; THYROID NODULE; TUMOR MARKERS, BIOLOGICAL;

EID: 81855180887     PISSN: 10529551     EISSN: 15334066     Source Type: Journal    
DOI: 10.1097/PDM.0b013e31821a59f1     Document Type: Article

References (48)

1. Welker MJ, Orlov D. Thyroid nodules. Am Fam Physician. 2003; 67:559-566.
2. Belfiore A, La Rosa GL, La Porta GA, et al. Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. Am J Med. 1992;93:363-369.
3. Gharib H, Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med. 1993;118:282-289. (Pubitemid 23046388)
4. Baloch ZW, LiVolsi VA. Fine-needle aspiration of thyroid nodules: past, present, and future. Endocr Pract. 2004;10:234-241.
5. Carpi A, Nicolini A, Gross MD, et al. Controversies in diagnostic approaches to the indeterminate follicular thyroid nodule. Biomed Pharmacother. 2005;59:517-520. (Pubitemid 41642951)
6. Baloch ZW, Fleisher S, LiVolsi VA, et al. Diagnosis of "follicular neoplasm": a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol. 2002;26:41-44. (Pubitemid 34037526)
7. Rodrigo JP, Rinaldo A, Devaney KO, et al. Molecular diagnostic methods in the diagnosis and follow-up of well-differentiated thyroid carcinoma. Head Neck. 2006;28:1032-1039. (Pubitemid 44630944)
8. Eszlinger M, Paschke R. Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Mol Cell Endocrinol. 2010;322:29-37.
9. Volante M, Bozzalla-Cassione F, Orlandi F, et al. Diagnostic role of galectin-3 in follicular thyroid tumors. Virchows Arch. 2004;444: 309-312. (Pubitemid 38553634)
10. Sanabria A, Carvalho AL, Piana de Andrade V, et al. Is galectin-3 a good method for the detection of malignancy in patients with thyroid nodules and a cytologic diagnosis of "follicular neoplasm"? A critical appraisal of the evidence. Head Neck. 2007;29:1046-1054.
11. Dumic J, Dabelic S, Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760:616-635. (Pubitemid 44382499)
12. Collet JF, Hurbain I, Prengel C, et al. Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples. Br J Cancer. 2005;93:1175-1181. (Pubitemid 41670703)
13. Bartolazzi A, Gasbarri A, Papotti M, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet. 2001;357:1644-1650. (Pubitemid 32568236)
14. Bartolazzi A, Orlandi F, Saggiorato E, et al. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multi-centre study. Lancet Oncol. 2008;9:543-549.
15. Naor D, Nedvetzki S, Golan I, et al. CD44 in cancer. Crit Rev Clin Lab Sci. 2002;39:527-579. (Pubitemid 35425379)
16. Gasbarri A, Martegani MP, Del Prete F, et al. Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol. 1999;17:3494-3502. (Pubitemid 29517920)
17. Gu J, Daa T, Kashima K, et al. Expression of splice variants of CD44 in thyroid neoplasms derived from follicular cells. Pathol Int. 1998;48:184-190. (Pubitemid 28204790)
18. Ermak G, Gerasimov G, Troshina K, et al. Deregulated alternative splicing of CD44 messenger RNA transcripts in neoplastic and nonneoplastic lesions of the human thyroid. Cancer Res. 1995;55: 4594-4598.
19. Maruta J, Hashimoto H, Yamashita H, et al. Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguish-ing follicular carcinoma from adenoma. Diagn Cytopathol. 2004;31: 392-396. (Pubitemid 39578578)
20. Matesa N, Samija I, Kusic Z. Galectin-3 and CD44v6 positivity by RT-PCR method in fine needle aspirates of benign thyroid lesions. Cytopathology. 2007;18:112-116. (Pubitemid 46496708)
21. Matesa N, Samija I, Kusic Z. Accuracy of fine needle aspiration biopsy with and without the use of tumor markers in cytologically indeterminate thyroid lesions. Coll Antropol. 2010;34:53-57.
22. Takano T, Sumizaki H, Amino N. Detection of CD44 variants in fine needle aspiration biopsies of thyroid tumor by RT-PCR. J Exp Clin Cancer Res. 1997;16:267-271. (Pubitemid 27454935)
23. Niedziela M, Maceluch J, Korman E. Galectin-3 is not an universal marker of malignancy in thyroid nodular disease in children and adolescents. J Clin Endocrinol Metab. 2002;87:4411-4415.
24. Pineda P, Rojas P, Liberman C, et al. Detection of malignancy markers in thyroid nodules by reverse transcriptase polymerase chain reaction (RT-PCR). Rev Med Chil. 2003;131:965-972.
25. World Medical Association. World Medical Association Declara-tion of Helsinki-Ethical Principles for Medical Research Involving Human Subjects. 2008. Available at: http://www.wma.net/en/30 publications/10policies/b3/index.html. [Accessed December 8, 2010].
26. Ditkoff BA, Marvin MR, Yemul S, et al. Detection of circulating thyroid cells in peripheral blood. Surgery. 1996;120:959-964.
27. Battayani Z, Grob JJ, Xerri L, et al. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patientswith melanoma. Arch Dermatol. 1995;131:443-447.
28. Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol. 2009;132:658-665.
29. Pagedar NA, Chen DH, Wasman JK, et al. Molecular classification of thyroid nodules by cytology. Laryngoscope. 2008;118:692-696. (Pubitemid 351496750)
30. Samija I, Matesa N, Lukac J, et al. Thyroid fine-needle aspiration samples inadequate for reverse transcriptase-polymerase chain reactionanalysis. Cancer. 2008;114:187-195. (Pubitemid 351969238)
31. Aratake Y, Umeki K, Kiyoyama K, et al. Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules. Diagn Cytopathol. 2002;26:366-372. (Pubitemid 34596007)
32. Martins L, Matsuo SE, Ebina KN, et al. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. J Clin Endocrinol Metab. 2002;87:4806-4810. (Pubitemid 35247079)
33. Bartolazzi A, Papotti M, Orlandi F. Methodological considerations regarding the use of galectin-3 expression analysis in preoperative evaluation of thyroid nodules. J Clin Endocrinol Metab. 2003;88: 950; author reply 950-951.
34. Takano T, Miyauchi A, Matsuzuka F, et al. Ubiquitous expression of galectin-3 mRNA in benign and malignant thyroid tumors. Cancer Lett. 2003;199:69-73. (Pubitemid 37088140)
35. Mehrotra P, Okpokam A, Bouhaidar R, et al. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology. 2004;45:493-500. (Pubitemid 39524324)
36. Oestreicher-Kedem Y, Halpern M, Roizman P, et al. Diagnostic value ofgalectin-3 as a marker for malignancy in follicular patterned thyroid lesions. Head Neck. 2004;26:960-966. (Pubitemid 39488123)
37. Coli A, Bigotti G, Zucchetti F, et al. Galectin-3, a marker ofwell-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology. 2002;40:80-87. (Pubitemid 34107385)
38. Giannini R, Faviana P, Cavinato T, et al. Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. Thyroid. 2003;13:765-770. (Pubitemid 37070157)
39. Kawachi K, Matsushita Y, Yonezawa S, et al. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol. 2000;31:428-433. (Pubitemid 30262863)
40. Bernet VJ, Anderson J, Vaishnav Y, et al. Determination of galectin-3 messenger ribonucleic acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab. 2002;87:4792-4796. (Pubitemid 35247077)
41. Feilchenfeldt J, Totsch M, Sheu S, et al. Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry. Mod Pathol. 2003;16:1117-1123. (Pubitemid 37414206)
42. Kusic Z, Novosel SA, Dabelic N, et al. Croatia has reached iodine sufficiency. J Endocrinol Invest. 2003;26:738-742. (Pubitemid 37448467)
43. Znaor A. Cancer Incidence in Croatia 2003-2007. Bulletins No 27-31. Zagreb: Croatian National Institute of Public Health; 2009.
44. Saggiorato E, De Pompa R, Volante M, et al. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer. 2005;12: 305-317. (Pubitemid 40896449)
45. Prasad ML, Pellegata NS, Huang Y, et al. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol. 2005;18:48-57. (Pubitemid 40128094)
46. Rossi ED, Raffaelli M, Mule' A, et al. Simultaneous immunohis-tochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology. 2006;48:795-800. (Pubitemid 43800938)
47. Nakamura N, Erickson LA, Jin L, et al. Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma. Endocr Pathol. 2006;17:213-223.
48. Hooft L, van der Veldt AAM, Hoekstra OS, et al. Hexokinase III, cyclin A and galectin-3 are over expressed in malignant follicular thyroid nodules. Clin Endocrinol (Oxf). 2008;68:252-257.